8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 28, 2026·SEC
Quince Therapeutics, Inc.(QNCX)Earnings, Financials & Key Ratios
QNCX•NASDAQ
$16.98
Price updated Jul 6, 2026
AboutQuince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$50M+11.9%
- Net Income-$84M-47.8%
- EPS (Diluted)-336.00-28.2%
QNCX Price & Volume
Quince Therapeutics, Inc. (QNCX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Masks Structural Liquidity Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and dilution
Key Thesis Takeaways
- Quince Therapeutics remains a high-risk, clinical-stage entity characterized by a total lack of revenue generation and persistent operational losses that have eroded equity to $15.7 million as of 2026Q1.
- The company's reliance on external financing to support its NOV004 program is underscored by a history of negative free cash flow, which reached an outflow of $7.6 million in the most recent quarter.
- Investors should remain cautious as the firm's reliance on non-operating accounting adjustments to report a $35.9 million net income in 2026Q1 obscures the underlying reality of its ongoing cash consumption and potential for further shareholder dilution.
Verdict Logic
the company's reliance on external capital to cover consistent quarterly cash burns, such as the $7.6 million negative free cash flow in 2026Q1, presents an unacceptable risk of further dilution for equity holders.
QNCX Growth Metrics
Quince Therapeutics, Inc. (QNCX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM45.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.18%
Return on Capital
10 Years-60.25%
5 Years-48.01%
3 Years-43.59%
Last Year-64.04%
QNCX Recent Earnings
Quince Therapeutics, Inc. (QNCX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (38%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.59+54.6%
$1.30
Rev
—
—
Q2 2026
Apr 10, 2026Metric
Actual
Est
EPS
$4.30-2292.9%
$0.18
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.25-25.0%
$0.20
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.34-21.4%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.59vs $1.30+54.6% | — |
| Q2 2026 | Apr 10, 2026 | $4.30vs $0.18-2292.9% | — |
| Q4 2025 | Nov 12, 2025 | $0.25vs $0.20-25.0% | — |
| Q3 2025 | Aug 11, 2025 | $0.34vs $0.28-21.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Quince Therapeutics, Inc. (QNCX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.98 | $4.73M | -0.05 | — | — | — | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $85.44 | $7.09B | 10.98 | 114.51% | -22.58% | — | — | |
| $374.68 | $11.05B | 54.78 | 33.94% | 53.92% | 19.25% | — |
Compare QNCX vs Peers
Quince Therapeutics, Inc. (QNCX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QNCX SEC Filings & Documents
Quince Therapeutics, Inc. (QNCX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when QNCX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QNCX Frequently Asked Questions
Quince Therapeutics, Inc. (QNCX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is QNCX profitable?
Quince Therapeutics, Inc. (QNCX) reported a net loss of $33.0M for fiscal year 2025.
Dividend & Returns
What is Quince Therapeutics, Inc.'s free cash flow?
Quince Therapeutics, Inc. (QNCX) had negative free cash flow of $39.7M in fiscal year 2025, likely due to heavy capital investments.